{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:15:58Z","timestamp":1777709758546,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Chronic limb-threatening ischaemia (CLTI) entails dismal outcomes and is an absolute indication to lower extremity revascularization (LER) whenever possible. Antithrombotic therapy is here crucial, but available evidence on best strategies (choice of drugs, combinations, duration) is scarce. We conducted a European internet-based survey on physicians\u2019 use of antithrombotic therapy after revascularization for CLTI, under the aegis of the ESC Working Group on Aorta and Peripheral Vascular Disease in collaboration with other European scientific societies involved in CLTI management and agreeing to send the survey to their affiliates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>225 respondents completed the questionnaire. Antithrombotic therapy following surgical\/endovascular LER varies widely across countries and specialties, with dedicated protocols reported only by a minority (36%) of respondents. Dual antiplatelet therapy with aspirin and clopidogrel is the preferred choice for surgical (37%) and endovascular (79%) LER. Dual pathway inhibition (DPI) with aspirin and low-dose rivaroxaban is prescribed by 16% of respondents and is tightly related to the availability of reimbursement (OR 6.88; 95% CI 2.60\u201318.25) and to the choice of clinicians rather than of physicians performing revascularization (OR 2.69; 95% CI 1.10\u20136.58). A\u00a0\u2265\u00a06 months-duration of an intense (two-drug) postprocedural antithrombotic regimen is more common among surgeons than among medical specialists (OR 2.08; 95% CI 1.10\u20133.94). Bleeding risk assessment is not standardised and likely underestimated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Current antithrombotic therapy of CLTI patients undergoing LER remains largely discretional, and prescription of DPI is related to reimbursement policies. An individualised assessment of thrombotic and bleeding risks is largely missing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac055","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T21:16:33Z","timestamp":1665263793000},"page":"201-207","source":"Crossref","is-referenced-by-count":14,"title":["Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-9804","authenticated-orcid":false,"given":"Marco","family":"De Carlo","sequence":"first","affiliation":[{"name":"Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana , 56124 Pisa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-5355","authenticated-orcid":false,"given":"Oliver","family":"Schlager","sequence":"additional","affiliation":[{"name":"Division of Angiology, 2nd Department of Medicine, Medical University of Vienna , 1090 Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9650-3822","authenticated-orcid":false,"given":"Lucia","family":"Mazzolai","sequence":"additional","affiliation":[{"name":"Division of Angiology, Heart and Vessel department, Lausanne University Hospital (CHUV) , 1011 Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[{"name":"Division of Angiology, Medical University Graz , 8036 Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-1761","authenticated-orcid":false,"given":"Christine","family":"Espinola-Klein","sequence":"additional","affiliation":[{"name":"Section Angiology, Department of Cardiology, Cardiology I, University Medical Center Mainz , 55131 Mainz ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Staub","sequence":"additional","affiliation":[{"name":"Division of Angiology, University Hospital Basel, University of Basel , 4031 Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital, and INSERM 1094 & IRD 270, University of Limoges , 87042 Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-6288","authenticated-orcid":false,"given":"Henrik","family":"Sillesen","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, and Department of Clinical Medicine, University of Copenhagen , 2100 Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-6439","authenticated-orcid":false,"given":"Sebastian","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Heart Centre Hamburg, University Medical Centre Hamburg-Eppendorf , 20246 Hamburg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-0988","authenticated-orcid":false,"given":"Maarit","family":"Venermo","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Helsinki University Hospital and University of Helsinki , 00029 Helsinki ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-6689","authenticated-orcid":false,"given":"Jill","family":"Belch","sequence":"additional","affiliation":[{"name":"The Institute of Cardiovascular Research, University of Dundee , DD19SY Dundee, Ninewells, Scotland ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana , 56124 Pisa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[{"name":"Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana , 56124 Pisa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"2025082502561927800_bib1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2025082502561927800_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025082502561927800_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1024\/0301-1526\/a000945","article-title":"International public awareness of peripheral artery disease","volume":"50","author":"Bauersachs","year":"2021","journal-title":"Vasa"},{"key":"2025082502561927800_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1570161117666190206234606","article-title":"Antithrombotic therapy for peripheral revascularisation","volume":"18","author":"De Carlo","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"2025082502561927800_bib5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082502561927800_bib6","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","article-title":"Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur Heart J"},{"key":"2025082502561927800_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/eurheartj\/ehy047","article-title":"The re-birth of an ESC working group","volume":"39","author":"De Carlo","year":"2018","journal-title":"Eur Heart J"},{"key":"2025082502561927800_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/0003319720976823","article-title":"Evolution of major amputation risk in patients hospitalized in France for critical limb ischemia: the COPART registry","volume":"72","author":"Coudene","year":"2021","journal-title":"Angiology"},{"key":"2025082502561927800_bib9","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/eurheartj\/ehac016","article-title":"Sex-related differences in treatment and outcome of chronic limb-threatening ischaemia: a real-world cohort","volume":"43","author":"Makowski","year":"2022","journal-title":"Eur Heart J"},{"key":"2025082502561927800_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ehjcvp\/pvaa026","article-title":"Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease","volume":"7","author":"Lapebie","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025082502561927800_bib11","first-page":"1363","article-title":"Development and validation of a predictive model for bleeding after peripheral vascular intervention: a report from the national cardiovascular data registry peripheral vascular interventions registry","volume":"98","author":"Salisbury","year":"2021","journal-title":"Catheter Cardiovasc. Interv."},{"key":"2025082502561927800_bib12","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jcin.2019.03.012","article-title":"Bleeding complications in lower-extremity peripheral vascular interventions: insights from the NCDR PVI registry","volume":"12","author":"Bhardwaj","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2025082502561927800_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"2025082502561927800_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jvs.2015.01.051","article-title":"Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease","volume":"62","author":"Armstrong","year":"2015","journal-title":"J Vasc Surg"},{"key":"2025082502561927800_bib15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jvs.2016.05.098","article-title":"Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization","volume":"64","author":"Soden","year":"2016","journal-title":"J Vasc Surg"},{"key":"2025082502561927800_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejvs.2016.12.014","article-title":"Dual antiplatelet therapy improves outcome in diabetic patients undergoing endovascular femoropopliteal stenting for critical limb ischaemia","volume":"53","author":"Thott","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025082502561927800_bib17","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease","volume":"12","author":"Cho","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2025082502561927800_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvz036","article-title":"Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the european society of cardiology working group on cardiovascular pharmacotherapy in collaboration with the european society of cardiology working group on aorta and peripheral vascular diseases","volume":"6","author":"Savarese","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025082502561927800_bib19","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025082502561927800_bib20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"2025082502561927800_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvac023","article-title":"Long-Term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial","author":"Eikelboom","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025082502561927800_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvac028","article-title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA registry","author":"Fox","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025082502561927800_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejvs.2021.05.028","article-title":"External applicability of the COMPASS and VOYAGER-PAD trials on patients with symptomatic lower extremity artery disease in france: the COPART registry","volume":"62","author":"Lapebie","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025082502561927800_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejvs.2021.10.026","article-title":"Revascularisation for symptomatic peripheral artery disease: external applicability of the VOYAGER PAD trial","volume":"63","author":"Sogaard","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac055\/46543497\/pvac055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/3\/201\/49806060\/pvac055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/3\/201\/49806060\/pvac055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T06:56:28Z","timestamp":1756104988000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/3\/201\/6754319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,10,8]]},"published-print":{"date-parts":[[2023,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac055","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2022,10,8]]}}}